<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38153113</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1437-4331</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Clinical chemistry and laboratory medicine</Title><ISOAbbreviation>Clin Chem Lab Med</ISOAbbreviation></Journal><ArticleTitle>Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus.</ArticleTitle><Pagination><StartPage>1237</StartPage><EndPage>1247</EndPage><MedlinePgn>1237-1247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/cclm-2023-1007</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis worldwide. HEV RNA detection is the gold standard for HEV infection diagnosis and PCR methods are commonly used but are usually time-consuming and expensive, resulting in low detection efficiency and coverage, especially in low-income areas. Here, we developed a simpler and more accessible HEV RNA detection method based on CRISPR-Cas13a system.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 265 samples of different types and sources, including 89 positive samples and 176 negative samples, were enrolled for evaluations. The sensitivity and specificity of the Cas13a-crRNA detection system were evaluated. The World Health Organization reference panel for HEV genotypes was used to evaluate the capability for detecting different HEV genotypes. The validity of the assay was compared with RT-qPCR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 95 % limits of detection (LOD) of Cas13a-crRNA-based fluorescence assay and strip assay were 12.5 and 200 IU/mL, respectively. They did not show cross-reactivity with samples positive for hepatitis A virus, hepatitis B virus, hepatitis C virus, coxsackievirus A16, rotavirus, enterovirus 71, norovirus or enteropathic <i>Escherichia coli</i>. Different HEV genotypes (HEV1-4) can be detected by the assay. Compared to RT-qPCR, the positive predictive agreements of Cas13a-crRNA-based fluorescence and strip assay were 98.9 % (95 % CI: 93.9-99.8 %) and 91.0 % (95 % CI: 83.3-95.4 %), respectively. The negative predictive agreements were both 100 % (95 % CI: 97.8-100 %).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, we established a rapid and convenient HEV RNA detection method with good sensitivity and specificity based on CRISPR-Cas13a system, providing a new option for HEV infection diagnosis.</AbstractText><CopyrightInformation>© 2023 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Manyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qiyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infection Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Haiwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Chem Lab Med</MedlineTA><NlmUniqueID>9806306</NlmUniqueID><ISSNLinking>1434-6621</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016752" MajorTopicYN="Y">Hepatitis E virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016751" MajorTopicYN="Y">Hepatitis E</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR-Cas13a</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">hepatitis E virus</Keyword><Keyword MajorTopicYN="N">nucleic acid detection</Keyword><Keyword MajorTopicYN="N">recombinase polymerase amplification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>29</Day><Hour>13</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>28</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>28</Day><Hour>7</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38153113</ArticleId><ArticleId IdType="doi">10.1515/cclm-2023-1007</ArticleId><ArticleId IdType="pii">cclm-2023-1007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nimgaonkar, I, Ding, Q, Schwartz, RE, Ploss, A. Hepatitis E virus: advances and challenges. Nat Rev Gastroenterol Hepatol 2018;15:96–110. https://doi.org/10.1038/nrgastro.2017.150 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn, R, Wetten, A, McPherson, S, Donnelly, MC. Viral hepatitis in 2021: the challenges remaining and how we should tackle them. World J Gastroenterol 2022;28:76–95. https://doi.org/10.3748/wjg.v28.i1.76 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i1.76</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar, N, Izopet, J, Pavio, N, Aggarwal, R, Labrique, A, Wedemeyer, H, et al.. Hepatitis E virus infection. Nat Rev Dis Prim 2017;3:17086. https://doi.org/10.1038/nrdp.2017.86 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.86</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Z, de Man, RA, Kamar, N, Pan, Q. Chronic hepatitis E: advancing research and patient care. J Hepatol 2022;77:1109–23. https://doi.org/10.1016/j.jhep.2022.05.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxall, E, Herborn, A, Kochethu, G, Pratt, G, Adams, D, Ijaz, S, et al.. Transfusion-transmitted hepatitis E in a ‘nonhyperendemic’ country. Transfus Med 2006;16:79–83. https://doi.org/10.1111/j.1365-3148.2006.00652.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3148.2006.00652.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallian, P, Pouchol, E, Djoudi, R, Lhomme, S, Mouna, L, Gross, S, et al.. Transfusion-transmitted hepatitis E virus infection in France. Transfus Med Rev 2019;33:146–53. https://doi.org/10.1016/j.tmrv.2019.06.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2019.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala, H, Hewitt, PE, Reynolds, C, Pearson, C, Haywood, B, Tettmar, KI, et al.. Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening. Euro Surveill 2019;24. https://doi.org/10.2807/1560-7917.es.2019.24.10.1800386 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2019.24.10.1800386</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreier, J, Knabbe, C, Vollmer, T. Transfusion-transmitted hepatitis E: NAT screening of blood donations and infectious dose. Front Med 2018;5:5. https://doi.org/10.3389/fmed.2018.00005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, C, Wang, Y. Laboratory diagnosis of HEV infection. Adv Exp Med Biol 2016;948:191–209. https://doi.org/10.1007/978-94-024-0942-0_11 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-024-0942-0_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton, HR, Kamar, N, Baylis, SA, Moradpour, D, Wedemeyer, H, Negro, F. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol 2018;68:1256–71. https://doi.org/10.1016/j.jhep.2018.03.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson, TR, Saroj, SD, Llewellyn, AC, Tzeng, YL, Weiss, DS. A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature 2013;497:254–7. https://doi.org/10.1038/nature12048 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa, MI, Makhawi, AM. SHERLOCK and DETECTR: CRISPR-Cas systems as potential rapid diagnostic tools for emerging infectious diseases. J Clin Microbiol 2021;59:e00745-20. https://doi.org/10.1128/jcm.00745-20 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00745-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner, MJ, Koob, JG, Gootenberg, JS, Abudayyeh, OO, Zhang, F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 2019;14:2986–3012. https://doi.org/10.1038/s41596-019-0210-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-019-0210-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J, Macdonald, J, von Stetten, F. Review: a comprehensive summary of a decade development of the recombinase polymerase amplification. Analyst 2018;144:31–67. https://doi.org/10.1039/c8an01621f .</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c8an01621f</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostyusheva, A, Brezgin, S, Babin, Y, Vasilyeva, I, Glebe, D, Kostyushev, D, et al.. CRISPR-Cas systems for diagnosing infectious diseases. Methods 2022;203:431–46. https://doi.org/10.1016/j.ymeth.2021.04.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2021.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fozouni, P, Son, S, Díaz de León Derby, M, Knott, GJ, Gray, CN, D’Ambrosio, MV, et al.. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 2021;184:323–33.e9. https://doi.org/10.1016/j.cell.2020.12.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhrvold, C, Freije, CA, Gootenberg, JS, Abudayyeh, OO, Metsky, HC, Durbin, AF, et al.. Field-deployable viral diagnostics using CRISPR-Cas13. Science 2018;360:444–8. https://doi.org/10.1126/science.aas8836 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aas8836</ArticleId></ArticleIdList></Reference><Reference><Citation>Jothikumar, N, Cromeans, TL, Robertson, BH, Meng, XJ, Hill, VR. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. J Virol Methods 2006;131:65–71. https://doi.org/10.1016/j.jviromet.2005.07.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2005.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M, Li, T, Hao, X, Liu, Y, Lan, H, Zhou, C. Preliminary investigation of hepatitis E virus detection by a recombinase polymerase amplification assay combined with a lateral flow strip. J Vet Diagn Invest 2023;35:395–8. https://doi.org/10.1177/10406387231167119 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10406387231167119</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmakov, S, Smargon, A, Scott, D, Cox, D, Pyzocha, N, Yan, W, et al.. Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 2017;15:169–82. https://doi.org/10.1038/nrmicro.2016.184 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2016.184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski, MM, Abudayyeh, OO, Gootenberg, JS, Zhang, F, Collins, JJ. CRISPR-based diagnostics. Nat Biomed Eng 2021;5:643–56. https://doi.org/10.1038/s41551-021-00760-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-021-00760-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrulolum, H, Tarrahimofrad, H, Rouzbahani, FN, Nooraei, S, Sameh, MM, Hajizade, A, et al.. Potential of CRISPR/Cas system as emerging tools in the detection of viral hepatitis infection. Virol J 2023;20:91. https://doi.org/10.1186/s12985-023-02048-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02048-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Domanović, D, Tedder, R, Blümel, J, Zaaijer, H, Gallian, P, Niederhauser, C, et al.. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill 2017;22:30514. https://doi.org/10.2807/1560-7917.es.2017.22.16.30514 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2017.22.16.30514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, CKM, Wong, SH, Law, AWH, Law, MF. Transfusion-transmitted hepatitis E: what we know so far? World J Gastroenterol 2022;28:47–75. https://doi.org/10.3748/wjg.v28.i1.47 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i1.47</ArticleId></ArticleIdList></Reference><Reference><Citation>Germer, JJ, Ankoudinova, I, Belousov, YS, Mahoney, W, Dong, C, Meng, J, et al.. Hepatitis E virus (HEV) detection and quantification by a real-time reverse transcription-PCR assay calibrated to the World Health Organization standard for HEV RNA. J Clin Microbiol 2017;55:1478–87. https://doi.org/10.1128/jcm.02334-16 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.02334-16</ArticleId></ArticleIdList></Reference><Reference><Citation>Girón-Callejas, A, Clark, G, Irving, WL, McClure, CP. In silico and in vitro interrogation of a widely used HEV RT-qPCR assay for detection of the species Orthohepevirus A. J Virol Methods 2015;214:25–8. https://doi.org/10.1016/j.jviromet.2014.11.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2014.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Frías, M, López-López, P, Zafra, I, Caballero-Gómez, J, Machuca, I, Camacho, Á, et al.. Development and clinical validation of a pangenotypic PCR-based assay for the detection and quantification of hepatitis E virus (Orthohepevirus A genus). J Clin Microbiol 2021;59:e02075-20. https://doi.org/10.1128/jcm.02075-20 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.02075-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordes, AK, Goudeva, L, Lütgehetmann, M, Wenzel, JJ, Behrendt, P, Wedemeyer, H, et al.. Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. J Hepatol 2022;76:46–52. https://doi.org/10.1016/j.jhep.2021.08.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.08.018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>